Patenting the sun: Enclosing the scientific commons and transforming the university - Ethical concerns

Drug Development Research

Volumn 63, Issue 3, 2004, Pages 139-149

  Triggle, David J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Acts of enclosure; Bayh Dole act; Ethics; Patents; The commons; University industry relationships

Indexed keywords

ETHICS; HEALTH CARE POLICY; PATENT; REVIEW; SCIENCE; UNIVERSITY;

EID: 16444379381     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10404     Document Type: Review

References (143)

1. Abbott A. 2004. Clinicians win fight to overturn patent for breastcancer gene. Nature 429:329.
2. Agres T. 2002. Universities war with big pharma. Scientist 16 (August 19).
3. Alliance for Human Research Protection. 2004. Memo from Andrew D. Mosholder: Suicidality in pediatrie clinical trials with paroxetine and other antidepressant drugs: follow-up to 9-4-03 consult. www.ahrp.org/risks/ SSRImosholder/index.html.
4. Altbach PG. 2004. The costs and benefits of world-class universities. Academe. (January-February). www.aaup.org/publications/Academe/2004/04jf/ 04jfaltb.htm.
5. Association of University Technology Managers. 2003. AUTM Licensing; survey: FY 2002. www.autm.net
6. Baird D. 1997. Scientific instrument making, epistemology and the conflict between the gift and commodity economies. Techne: Electron J Soc Philos Technol 2. http://scholar.lib.vt.edu/ejour nals/spt/v2n3n4/baird.html. Quoted by J. Kovac, Gifts and commodities in chemistry, www.hyle.org/journal/issues/7/ kovac.htm.
7. Baird D. 1997. Scientific instrument making, epistemology and the conflict between the gift and commodity economies. Techne: Electron J Soc Philos Technol 2. http://scholar.lib.vt.edu/ejour nals/spt/v2n3n4/baird.html. Quoted by J. Kovac, Gifts and commodities in chemistry, www.hyle.org/journal/issues/7/ kovac.htm.
8. Baird D, Downie J, Thompson J. 2002. Clinical trials and industry, Science 297:2211-2212.
9. Baltimore D, Sen R, Sharp PA. 2002. Nuclear factors associated with transcriptional regulation. USP 6,410, 516.
10. Benkler Y. 2004. Commons-based strategies and the problems of patents. Science 305:1110-1111.
11. Birchard K. 2002. U. of Toronto settles dispute over academic freedom and company-sponsored research. Chron Higher Educ (November 1).
12. Blumenstyk G. 2003. University earnings from inventions hit nearly $1 billion in 2002, survey finds. Chron Higher Educ (December 9).
13. Blumenstyk G. 2004. Peer reviewers give thumbs down to Berkeley-Novartis deal. Chron Higher Educ (July 30).
14. Bodenheimer T. 2000. Uneasy alliance: clinical investigators and the pharmaceutical industry. New Engl J Med 342:1539-1544.
15. Bok D. 2003. Universities in the market place. Princeton. NJ: Princeton University Press.
16. Bollier D. 2001. Public assets, private profits. Reclaiming the American commons in an age of market enclosure. The New America Foundation, Washington, D.C. www.Bollier.org/pdf PA_Report.pdf
17. Bollier D. 2002. Silent theft. The private plunder of our common wealth. New York: Routledge.
18. Bollier D. 2004. The clash of market and commons. Presented at the Conscience and Science Forum, Simon Fraser University, April 29. Burnaby, BC, Canada. www.bollier.org/reclaim.htm
19. Booth T, Turk JL. 2001. Letter to Robert Birgeneau, President, University of Toronto. www.pharmapolitics.com/birgeneau.html.
20. Boyd EA, Bero LA. 2000. Assessing faculty financial relationships with industry, A case study. JAMA 284:2209-2214.
21. Bremer HW. 2001. The first two decades of the Bayh-Dole act as public policy. www.nasulgc.org/COTT/Bayh-Dole/Brmer_speech.htm.
22. Brickley P. 2003. Patent rights wrangle puts law in question. Scientist (March 10):42-43.
23. Bronfenbrenner U, McClelland P, Wethington E, Moen P, Ceci SJ. 1996. The state of Americans. New York: Free Press.
24. Brown JR. 2000. Privatizing the university: the new tragedy of the commons. Science 290:1701-1702.
25. Buck SJ. 1998. The global commons. An introduction. Island Press, New York.
26. Burress C. 2004. Probe of research pact at Cal released. While no harm was done, avoiding such deals in the future. San Francisco Chronicle (July 31).
27. Burton JH, Strauss J, 2000. How can the developing world protect itself from biotech patent-holders? Nature 406:455.
28. Burton TH. 2000. Unfavorable drug study sparks battle over publication of results. Wall Street Journal (November 1).
29. Bush V. 1945. Science: the endless frontier. A report to the President by Vannevar Bush, Director of the Office of Scientific Research and Development, July 1945. www.nsf.gov/od/lpa/nsf50/vbush/1945.htm.
30. Cho MK, Shohara R, Schissel A, Rennie D. 2000. Policies on faculty conflicts of interest at US universities. JAMA 284:2203-2208.
31. Coghlan A. 1998. The price of profit. New Scientist (May 26): 20-21.
32. Commission on Intellectual Property Rights (CIPR). 2002. September. London, www.iprcommission.org
33. Cyranoski D. 2003. This protein belongs to... Nature 426:10-11.
34. Daniels, N, Kennedy B, Kawachi I. 2000. Is inequality bad for our health? Boston: Beacon Press.
35. Davidoff F. DeAngelis CD, Drazen JM, Hoey J, Hojgaard L, Horton R, Kotzin S, Nicholls MG, Nylenna M, Overbeke AJPM, Sox HC, Van der Weyden MB, Wilkes MS. 2001. Sponsorship, authorship, and accountability. JAMA 286:1232-1234.
36. DeVol R, Wong P, Ki J, Bedroussian A, Koepp R. 2004, America's biotech and life science clusters. Milken Institute.www.mikleninstitute.org.
37. Dietz, T, Ostrom E, Stern PC. 2003. The struggle to govern the commons. Science 302:1907-1912.
38. Duderstadt JJ, Womack, FW. 2003. Beyond the crossroads. The future of the public university in America. Baltimore: Johns Hopkins University Press.
39. Dugger CW. 2004. Rights group seeks to halt Africa's losses in health care. New York Times (July 13).
40. Economic Policy Institute. 2004. Income picture. www.epinet.org.
41. Ehrenreich B. 2001. Nickel and dimed. New York: Metropolitan Books.
42. Eisenberg R. 1996. Public research and private development: patents and technology transfer in government-sponsored research. Virginia Law Rev 82:1663-1727.
43. Eisenberg R. 2003. Patent swords and shields. Science 299:1018-1019.
44. Eisenberg R. Nelson RR. 2002. Public vs. proprietary science. Daedalus (Spring 2002):89-101.
45. Engell J, Dangerfield A. 1998. Humanities in the age of money. Harvard Magazine. Accessed at www.harvardmagazine.com/ issues/mj98/forum.html
46. Epstein M. 2002. Safety of calcium antagonists as antihypertensive agents: an update. In: Epstein M. editor. Calcium antagonists in clinical medicine, 3rd ed. Philadelphia, PA: Hanley and Belfus. p 807-832.
47. Filmore D. 2004. The NIH "swivel chair." Mod Drug Discov (August):45-46.
48. Forrest B, Gross PR. 2004. Creationism's Trojan horse. Oxford: Oxford University Press.
49. Frank T. 2000. One market under God. New York: Anchor Books.
50. Galbraith JK. 2002. A perfect crime: global inequality. Daedalus (Winter):11-25.
51. Geiger RL. 2004. Knowledge and money. Research universities and the paradox of the marketplace. Stanford, CA: Stanford University Press.
52. Giamatti B. 1990. A free and civil place: the real world of the university. New York: Norton.
53. Gladwell M. 2000. The tipping point. How little things can make a big difference. New York: Little, Brown and Company.
54. Goozner M. 2004. Unrevealed: non-disclosure of conflicts of interest in four leading medical and scientific journals. Center for Science in the Public Interest. www.cspinet.org
55. Gould E. 2003. The University in a Corporate Culture. New Haven: Yale University Press.
56. Greenberg DS. 2001. Money and politics: political triumph and ethical erosion. Chicago: University of Chicago Press.
57. Greenberg DS. 2004. Conference deplores corporate influence on academic science. Lancet 362:302-303,
58. Hardin G. 1968. The tragedy of the commons. Science 162:1243-1248.
59. Hardin G. 1998. Extensions of the tragedy of the commons. Science 280:682.
60. Harris G. 2004. Antidepressant study seen to back expert. New York Times (August 20).
61. Heller MA. 1988. The tragedy of the anticommons: property in the transition from Marx to Markets. Harvard Law Rev 111:622-688.
62. Heller MA, Eisenberg RS. 1998. Can patents deter innovation? The anticommons in biomedical research. Science 280:698-701.
63. Jefferson T. 1813. In The Writings of Thomas Jefferson ed. AA. Lipscomb and AE. Berg, Washington, DC 1903-1904.
64. Jencks C. 2002, Does inequality matter? Daedalus (Winter):49-65.
65. Jureidini JN, Joecke CJ, Mansfield PR, Haby MM, Menkes DB, Tonkin AL. Efficacy and safety of antidepressants for children and adolescents. BMJ 328:879-883.
66. 6/L CD4 cell counts. JAMA 284:2193-2202.
67. Kapczynski A, Crone ET, Merson M. 2003. Global health and university patents. Science 301:1629.
68. Kennedy D. 2001. Enclosing the research commons. Science 294:2249.
69. Keung N. 2002. MS settles lawsuit with U of T over job. Toronto Star (May 1).
70. Kirp DL. 2003. Shakespeare, Einstein, and the bottom line. The marketing of higher education. Cambridge, MA: Harvard University Press.
71. Krimsky S. 2003. Science in the private interest. Oxford, UK: Rowan and Littlefield.
72. Lancet. 2004. Editorial. Depressing research. 363:1335.
73. Lessig L. 2001. The future of ideas: the fate of the commons in a connected world. New York: Random House.
74. Malakoff D. 2003. Judge turns Rochester's golden patent into lead. Science 299:1638-1639.
75. Malakoff D. 2004. NIH roils academe with advice on licensing DNA patents. Science 303:1757-1758.
76. Marshall E. 2003. Depth charges aimed at Columbia's "submarine patent." Science 301:448.
77. Maugh TH. 2000. Firm disputes handling of drug study. Los Angeles Times (November 1).
78. Mehta S. 2004. The emerging role of academia in commercializing innovation. Nature Med 22:21-24.
79. Menninger JR. 2001. Research is valuable. Let's give it away. Chron Higher Educ (September 14).
80. Merton RK. 1938. Science and the Social order. Philos Sci 5:321-337.
81. Merton RK. 1957. Priorities in Scientific discovers. Am Sociol Rev 22:635-659.
82. Merton RK. 1973. The sociology of science. Chicago: University of Chicago Press, p 267-278.
83. Merz JF. 1999. Disease gene patents: overcoming unethical constraints on clinical laboratory medicine. Clin Chem 45:324-330.
84. Merz JF, Kriss AG, Leonard DGB, Cho MK. 2002. Diagnostic testing fails the test. Nature 415:577-579.
85. Miller KW, Triggle DJ. 2002. Graduate education: another tragedy of the commons? Am J Pharm Ed 66:287-294.
86. Millnski M, Semmann D. Krambeck, H-J. 2002. Reputation helps solve the "tragedy of the commons." Nature 415:424-426.
87. Mishel L, Bernstein J, Schmitt J. 2001. The State of Working America. Ithaca, NY: Cornell University Press.
88. Montgomery D C. 2003. Marketing science, marketing ourselves. Academe (Summer) www.aaup.org/publications/Academe/03so/ 03somonth.htm.
89. More T Sir. Utopia. www.wwnorton.com/college/history/ralph/workbook/ ralprs22b.htm.
90. Muula AS, Mfutso-Bengo JM, Makoza J, Chatipwa E. The ethics of developed nations recruiting nurses from developing countries: the case of Malawi. Nurs Ethics 2003:10:433-38.
91. Nathan DG, Weatherall DJ. 2002. Academic freedom in clinical research. New Eng J Med 347:1368-1371.
92. National Institutes of Health. 2004. Conflict of interest report. www.nih.gov/about/ethics_COI_panelreport.pdf.
93. Nuffield Council on Bioethics. 2002. The ethics of patenting DNA. A discussion paper. www.nuffieldbioethics.org.
94. Ostrom E, Burger J, Field CB, Norgaard RB, Policansky D. 1999. Revisiting the commons: local lessons, global challenges. Science 284:278-282.
95. Patel V. 2003. Recruiting doctors from poor countries: the great brain robbery? BMJ 327:926-928.
96. Perakh M. 2004. Unintelligent design. Buffalo, NY: Prometheus Books.
97. Phillips K. 2002. Wealth and democracy: a political history of the American rich. New York: Broadway Books.
98. Phillips RL, Chen J, Okediji R, Burk D. 2004. Intellectual property rights and the public good. Scientist (July 19):8.
99. Polanyi JC. 1944. The great transformation. The political and economic origins of our time. Boston: Beacon Press.
100. Rai AK, Eisenbeg RS. 2003. Bagh-Dole Reform and the progress of biomedicine. Law and Contemp. problems 66:289-310.
101. Ready T. 2002. Company pushes broad-ranging patent claim. Nature Med 8:1048.
102. Rosenstock L, Lee LJ. 2002. Attacks on science: the risks to evidence-based policy. Am J Pub Health 92:14-18.
103. Royal Society of London. 2003. Keeping science open: the effects of intellectual property policy on the conduct of science. www.pubs.royalsoc.ac.uk.
104. Sarmiento A. 1999. He who pays the piper calls the tune. Gallie lecture delivered at the Annual Meeting of the Royal College of Physicians and Surgeons, September 23-24. www.mednet.ca/ html/info-spec9909.htm.
105. Schuchman M. 1998. Secrecy in science. The flock worker's lung investigation. Ann Intern Med 129:341-344.
106. Shuchman M. 2002. The Olivieri dispute: no end in sight? CMAJ 166:487.
107. Schulman KA, Seils DM., Timbie JW, Sugarman J, Dame LA, Weinfurt KP, Mark DB, Califf RM. 2002. A national survey of provisions in clinical trial agreements between medical schools and industry sponsors. New Engl J Med 347:1335-1341.
108. Shulman S. 1999. Owning the future. Boston: Houghton Mifflin.
109. Slaughter S, Leslie LL. 1997. Academic capitalism. Politics, policies and the entrepreneurial university. Baltimore: Johns Hopkins University Press.
110. Smith A. 1776. The Wealth of nations. Random House, New York. 1994 edition.
111. Smith JS. 1990. Patenting the sun. Polio and the Salk vaccine. New York: William Morrow.
112. Soley LC. 1995. Leasing the ivory tower. The corporate takeover of academia. Boston: South End Press.
113. Speth JG. 2004. Red sky at morning. New Haven, CT: Yale University Press.
114. Staedter T. 2003 Technol Rev (December 24).
115. Stelfox HT, Chua G, O'Rourke K, Detsky AS. 1998. Conflict of interest in the debate over calcium-channel antagonists. New Engl J Med 338:101-106.
116. Stiglitz JS. 2002. Globalization and its discontents. New York: Norton.
117. Stilwell B, Diallo K, Zurn P, Vujicic O, Poz MD. 2004. Migration of healthcare workers from developing countries: strategic approaches to its management. Bull WHO 82:595-600.
118. Stokes DE. 1997. Pasteur's quadrant. Basic science and technological innovation. Washington, DC: Brookings Institution Press.
119. Tauzin B. 2003 (December 8). Letter to Elias Zherhouni MD. http:// energycommerce.house.gov/108/Letters/12082003_1148print.htm.
120. Thompson J, Baird P, Downie J. 2002. Report of the Committee of Inquiry on the case involving Dr. Nancy Olivieri, the Hospital for Sick Children, the University of Toronto, and Apotex. Inc. www.dal.ca/committeeofinquiry.
121. Tonelson A. 2000. The race to the bottom. Boulder, CO: Westview Press.
122. Treneman A. 2000. Doctors at war. The Times (London) (December 14).
123. Triggle DJ. 2003. Medicines in the 21st century or pills, politics, potions, and profits: where is public policy? Drug Dev Res 59:269-291.
124. Triggle DJ, Miller KW. 2002. Doctoral education: another tragedy of the commons? Am J Pharm Ed 66:287-294.
125. Twitchell JB. 2004. Higher Ed., Inc. Wilson Q 26:46-59.
126. Vaidhyanathan S. 2001. Copyrights and Copywrongs: the rise of intellectual property and how it threatens creativity. New York: New York University Press.
127. Van der Werf M. 2001. University prevails in dispute with pharmaceutical company. Chron Higher Educ (September 13).
128. Veblen T. 1918. The higher learning in America: a memorandum on the conduct of universities by businessmen. Transaction Publishers, New York, NY.
129. Wagner C, Lee Y-C. 2004. The world should share its science. Financial Times (August 25).
130. Wallsten S. 2004a. High-tech cluster bombs. Why successful biotech hubs are the exception, not the rule. Nature 428:121-122.
131. Wallsten S. 2004b. Do science parks generate regional economic growth? An empirical analysis of their effects on job growth and venture capital. AEI-Brookings Joint Center for Regulatory Studies, www.aei-brookings.org
132. Warde I. 2001. For sale: US academic integrity. Le Monde Diplomatique (March). www.mondediplo.com/2001/03/11aca demic.
133. Warner TD, Roberts LW. 2004. Scientific integrity, fidelity and conflicts of interest. Curr Opin Psychiatry 17:381-385.
134. Washburn J. 2000. The kept university. Atlantic Monthly (March 1). Accessed: www.newamerica.net/templets/Documents/print.cfm? pg=article&DocID= 134&Prt=Yes.
135. Water R. 2004. FDA was urged to limit kid's antidepressants. San Francisco Chronicle (April 16).
136. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. 2004. selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 363:1341-1345.
137. Willdnson R G. 2000. Mind the gap. New Haven, CT: Yale University Press.
138. Williams-Jones B, 2002. History of a gene patent: tracing the development and application of commercial BRCA testing. Health Law J 10:123-146.
139. Williamson T. 2002. The transformation of rural England. Exeter, UK: University of Exeter Press.
140. Willman D. 2003. (a) Stealth merger: drug companies and government medical research. (b) A government accolade from a paid consultant. (c) A federal researcher who defended a client's lethal drug. (d) A cancer expert who aided studies using a drug wanted by a client. (e) A federal lab leader who made $1.4 million on the side. (f) A clinic chief's desire to "learn about industry." Los Angeles Times (December 7). Los Angeles, CA. www.latimes.com
141. Wolf A. 2002. Does education matter? Myths about education and economic growth. New York: Penguin Books.
142. Young DA, O'Banion MK, Winn VD. 2000. Method of inhibiting prostagianclin synthesis in human host. USP 6,048,850.
143. Ziman J. 2000. Real science. What it is, and what it means. Cambridge, UK: Cambridge University Press.